| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.1780370218 |
| P698 | PubMed publication ID | 7510487 |
| P2093 | author name string | Black C | |
| Vancheeswaran R | |||
| Chu S | |||
| Waegell W | |||
| Higley H | |||
| Persichitte K | |||
| P433 | issue | 2 | |
| P921 | main subject | limited systemic sclerosis | Q55786167 |
| P304 | page(s) | 278-288 | |
| P577 | publication date | 1994-02-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon | |
| P478 | volume | 37 |
| Q35843450 | 12E2: a cloned murine dermal cell with features of dermal dendrocytes and capacity to produce pathologic changes resembling early Kaposi's sarcoma |
| Q77995169 | Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary |
| Q37912251 | Biomarkers for skin involvement and fibrotic activity in scleroderma |
| Q38733580 | Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease |
| Q46949378 | CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts |
| Q34567929 | Current treatment options in systemic Sclerosis (Scleroderma). |
| Q36784652 | Cytokine profiles in localized scleroderma and relationship to clinical features |
| Q49072027 | European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. |
| Q44054533 | Evaluation of mean platelet volume in localized scleroderma |
| Q43709166 | Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis |
| Q79077949 | Exercise-induced changes in circulating levels of transforming growth factor-beta-1 in humans: methodological considerations |
| Q33566999 | Expression of ectopeptidases in scleroderma |
| Q34005595 | Fibroblast heterogeneity in physiological conditions and fibrotic disease |
| Q42278392 | Generalized morphea after breast cancer radiation therapy |
| Q41816319 | Getting out of a sticky situation: targeting the myofibroblast in scleroderma |
| Q34257607 | Histone deacetylase: a potential therapeutic target for fibrotic disorders |
| Q53594263 | Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. |
| Q37810508 | Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations |
| Q34906164 | Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial |
| Q91782511 | Immunopathogenesis of Juvenile Systemic Sclerosis |
| Q41220119 | Immunopathogenesis of systemic sclerosis |
| Q41808580 | Increased serum levels of TGFbeta1 in children with localized scleroderma. |
| Q71970874 | Increased susceptibility to oxidation of low‐density lipoproteins isolated from patients with systemic sclerosis |
| Q58785737 | Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1 |
| Q38022272 | Localized scleroderma |
| Q38516265 | Macro- and microvascular disease in systemic sclerosis |
| Q38902145 | Morphea and Eosinophilic Fasciitis: An Update |
| Q35169049 | Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being |
| Q36002290 | Osteopontin in systemic sclerosis and its role in dermal fibrosis |
| Q41220098 | Pathogenesis of scleroderma. Collagen |
| Q36282971 | Pediatric scleroderma: systemic or localized forms |
| Q33710621 | Periostin in Mature Stage Localized Scleroderma |
| Q33566799 | Plasma TGF beta in systemic sclerosis: a cross-sectional study. |
| Q47680876 | Polymorphisms of the TGF-beta1 promoter in tight skin (TSK) mice. |
| Q36965488 | Protective role for miR-9-5p in the fibrogenic transformation of human dermal fibroblasts. |
| Q40468537 | Regulation of connective tissue synthesis in systemic sclerosis. |
| Q28142724 | Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model |
| Q34747455 | Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis |
| Q74452502 | Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis |
| Q41679291 | Significant Correlation Between Connective Tissue Growth Factor Gene Expression and Skin Sclerosis in Tissue Sections from Patients with Systemic Sclerosis |
| Q35169046 | Systemic sclerosis: the susceptible host (genetics and environment). |
| Q33857618 | TGF-beta in blood: a complex problem |
| Q37786516 | Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis |
| Q41766529 | The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts |
| Q38828584 | The molecular pathogenesis of morphoea: from genetics to future treatment targets |
| Q38241227 | Transforming growth factor β--at the centre of systemic sclerosis |
| Q44024457 | Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers |
| Q37535719 | Transforming growth factor-β1 in plaque morphea |
| Q37351546 | Updates on morphea: role of vascular injury and advances in treatment |
| Q64046177 | [Systemic sclerosis: pathophysiology of a multifaceted disease] |
Search more.